September 8, 2016


Will Real-World Data Sway Course Of Novel Anticoagulant Market?

By Emily Hayes

A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer’s Xarelto.

read full article >